CureVac N.V. (CVAC)
- Previous Close
3.0200 - Open
3.0800 - Bid 2.9600 x 400
- Ask 3.0000 x 100
- Day's Range
2.9000 - 3.0950 - 52 Week Range
2.2150 - 6.9600 - Volume
1,038,092 - Avg. Volume
764,173 - Market Cap (intraday)
672.942M - Beta (5Y Monthly) 2.62
- PE Ratio (TTM)
-- - EPS (TTM)
-1.4000 - Earnings Date Nov 12, 2024 - Nov 18, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
7.99
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.
www.curevac.comRecent News: CVAC
View MorePerformance Overview: CVAC
Trailing total returns as of 9/27/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CVAC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CVAC
View MoreValuation Measures
Market Cap
675.19M
Enterprise Value
489.06M
Trailing P/E
--
Forward P/E
5.24
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
9.15
Price/Book (mrq)
1.60
Enterprise Value/Revenue
6.67
Enterprise Value/EBITDA
-0.66
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-24.52%
Return on Equity (ttm)
-54.30%
Revenue (ttm)
65.86M
Net Income Avi to Common (ttm)
-278.43M
Diluted EPS (ttm)
-1.4000
Balance Sheet and Cash Flow
Total Cash (mrq)
202.52M
Total Debt/Equity (mrq)
10.37%
Levered Free Cash Flow (ttm)
-222.1M